← All trials
NCT05920005
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Jul 1, 2024
- First posted
- Jun 27, 2023
- Last posted
- Aug 24, 2023
- Enrollment
- 698
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Albert Einstein Israelite HospitalLead sponsor
- Albert Einstein Israelite HospitalStudy director
- Libbs Farmacêutica LTDACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.